TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer

Medicine & Life Sciences

• Androgen Receptor Antagonists 100%
• Triple Negative Breast Neoplasms 79%
• Androgen Receptors 70%
• Phosphatidylinositol 3-Kinases 65%
• Multicenter Studies 57%
• 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 55%
• MDV 3100 38%
• Maximum Tolerated Dose 15%
• Progression-Free Survival 11%
• Breast Neoplasms 8%
• Exanthema 6%
• Neoplasms 6%
• Estrogen Receptors 6%
• Hyperglycemia 5%
• Disease Progression 5%
• Research Personnel 4%
• Safety 3%
• Proteins 2%
• Therapeutics 1%